Mon panier

Biotinylated Human IL-33 Protein, His,Avitag™ (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
IL3-H82H5-25ug
$395.00
IL3-H82H5-200ug
$1745.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    IL33, DV27, C9ORF26, IL1F11, NFHEV, DKFZp586H0523, DVS27, NFEHEV, RP11-575C20.2

  • Source

    Biotinylated Human IL-33, His,Avitag (IL3-H82H5) is expressed from human 293 cells (HEK293). It contains AA His 109 - Thr 270 (Accession # O95760-1).

    Predicted N-terminus: His

    Request for sequence
  • Molecular Characterization

    IL-33 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 21.9 kDa. The protein migrates as 28-33 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    IL-33 SDS-PAGE

    Biotinylated Human IL-33, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    IL-33 SEC-MALS

    The purity of Biotinylated Human IL-33, His,Avitag (Cat. No. IL3-H82H5) is more than 95% and the molecular weight of this protein is around 21-40 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     IL-33 ELISA

    Immobilized Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-33, His,Avitag (Cat. No. IL3-H82H5) with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  IL-33 ELISA

    Immobilized Biotinylated Human IL-33, His,Avitag (Cat. No. IL3-H82H5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Tozorakimab with a linear range of 0.2-8 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-BLI

     IL-33 BLI

    Loaded Human IL-1RL1, Fc Tag (Cat. No. IL1-H5250) on Protein A Biosensor, can bind with Biotinylated Human IL-33, His,Avitag (Cat. No. IL3-H82H5) an affinity constant of 1.81 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Interleukin 33 (IL33) is known as C9orf26, DKFZp586H0523, DVS27, NF-HEV, NFEHEV, RP11-575C20.2,and is a cytokine belonging to the IL-1 superfamily. IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. IL-33 mediates its biological effects by interacting with the receptors ST2 (aka IL1RL1) and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Interleukin-33

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    9 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte